Germany’s Formycon announced that Klinge Biopharma, the exclusive owner of the global commercialization rights of ...

Issue of Debt/BondStrong demand for Formycon 2025/2029 Bond leads to early closing of subscription period 24.06.2025 / 19:50 CET/CESTThe issuer is solely responsible for the content of this ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...